AstraZeneca PLC - Ebit

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Ebit" stands at 9.31 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

AstraZeneca PLC's third quarter result of 3.59 Billion USD for the item "Ebit" represents a decrease of -2.14 percent compared to it's second quarter result.

Also, AstraZeneca PLC's third quarter result of 3.59 Billion USD for the item "Ebit" represents an increase of 52.47 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 9.31 Billion USD for the item "Ebit" represents an increase of 15.31 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.4574 Billion United States Dollars compared to the value the year prior.
The 1 year change is -0.4574 Billion United States Dollars.
The 3 year change is 7.01 Billion United States Dollars.
The 5 year change is 4.98 Billion United States Dollars.
The 10 year change is 5.95 Billion United States Dollars.

The Serie's long term average value is 5.43 Billion United States Dollars. It's latest available value, on 09/30/2025, is 3.88 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is +9.82 Billion.
The Serie's change in United States Dollars from it's maximum value, on 12/31/2011, to it's latest available value, on 09/30/2025, is -4.03 Billion.